NCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
Clinical Trials
4 trialsNCT05394350 2024-11-08
MK-1088-002
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02880371 2022-06-16
A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Pfizer
Phase 1/2 Terminated
NCT02179918 2019-02-08
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
Pfizer
Phase 1 Completed